Explore 3 Stock Ideas & Industry Insights Download Free Report

Cannabics Pharmaceuticals Inc

Company price
0.0001 USD 0.00(0%)
Last update at 2026-11-13T20:11:00Z
VOLUME
67
Market Cap
0.37M

Momentum Score

…

CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.

Source: TradingView
The charts and visual representations are sourced from TradingView through embedded widgets. For any issues with chart display, please visit the TradingView website

Day Price Range
0.00
Low
0.00
High
52 Week Price Range
0.00
Low
0.00
High

Momentum Score

…
Loading momentum score…

A unique technical analysis driven score developed by Kalkine showing momentum in stock prices based on select technical indicators identified.

Score - Rating
>= 1 - Low / > 1 but < 2 - Below Average / > 2 but < 3 - Average / > 3 but < 4 - Above Average / > 4 - High
AI Summary

Cannabics Pharmaceuticals Inc develops cannabinoid-based therapeutics with a stated focus on oncology and personalized treatment approaches. Long-term growth drivers may include progress in clinical programs, regulatory acceptance of medical cannabis products, licensing or partnering opportunities, and wider clinical adoption of cannabinoid therapies. Investors may find exposure to a niche biotech pipeline attractive if programs advance and commercial pathways emerge.

Risk Score
High

Note: The summary and risk score provided above is created by AI and should not be construed as a recommendation of Kalkine.

Key Metrics*

Previous Close
0.00
Dividend Yield
-
Revenue TTM
0.00M
Revenue Per Share
-
Gross Profit TTM
0.00M
Debt / Equity
-0.48
ROE
-4289.36%
Net Debt
1.18M
ROCE
10.88%
Diluted EPS TTM
-

Key Financials*

Income Statement

Balance Sheet

Change in Cash

Total Operating Cash

Dividends Paid

Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Income before tax -0.31M -0.69M -3.71M -3.72M -3.19M
Net income -0.31M -0.69M -3.71M -3.72M -3.19M
Selling general administrative 0.27M 0.52M 0.91M 1.77M 0.83M
Gross profit - 0.13M - - -
Reconciled depreciation 0.00M 0.07M 0.16M 0.20M 0.22M
Ebit - -0.68M - -2.95M -2.60M
Ebitda -0.27M -0.60M - -3.52M -2.97M
Depreciation and amortization - 0.07M - - -
Operating income -0.27M -0.58M -0.93M -2.95M -2.60M
Other operating expenses 0.27M 0.71M - - -
Interest expense 0.04M 0.02M 0.00M 0.00M 0.00M
Net interest income -0.04M -0.02M -0.00M -0.00M -0.06M
Total revenue 0.00M 0.13M 0.41M 0.00M 0.00M
Total operating expenses 0.27M 0.71M 1.34M 2.95M 2.60M
Cost of revenue - 0.07M - - -
Total other income expense net -0.04M -0.11M -2.78M -0.77M -0.53M
Net income from continuing ops -0.31M -0.70M -3.71M -3.72M -3.19M
Net income applicable to common shares - - - -3.72M -3.19M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Total assets 0.02M 0.03M 0.50M 0.81M 3.08M
Other current assets 0.00M 0.00M - - 0.20M
Total liab 2.51M 2.51M 2.52M 2.44M 1.27M
Total stockholder equity -2.50M -2.48M -2.02M -1.63M 1.81M
Other current liab 1.27M 2.47M - 0.22M 0.22M
Common stock 0.06M 0.00M - 0.00M 0.01M
Capital stock 0.06M - 0.00M 0.00M 0.01M
Retained earnings -25.27M -24.95M -24.26M -20.55M -16.83M
Other liab - - - 0.00M -
Cash 0.02M 0.03M 0.13M 0.12M 1.39M
Total current liabilities 2.51M 2.51M 2.52M 2.44M 1.27M
Net debt 1.18M -0.03M 1.21M 1.64M -
Short term debt 1.20M - - - -
Short long term debt 1.20M - 1.34M 1.76M 0.87M
Short long term debt total 1.20M 1.30M - - -
Other stockholder equity 22.72M 22.47M - 0.88M 1.55M
Property plant equipment - - - 0.44M 0.64M
Total current assets 0.02M 0.03M 0.22M 0.20M 1.59M
Long term investments - - 0.00M 0.18M 0.85M
Net tangible assets - - - -1.63M 1.81M
Net receivables 0.00M 0.00M - - -
Accounts payable 0.05M 0.04M 0.34M 0.46M 0.18M
Non current assets total 0.00M - 0.27M 0.61M 1.49M
Breakdown 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Type yearly yearly yearly yearly yearly
Date 2025-08-31 2024-08-31 2023-08-31 2022-08-31 2021-08-31
Investments - 0.11M 0.02M 0.03M 0.65M
Change to liabilities - - - 0.28M -0.05M
Total cashflows from investing activities - 0.11M - 0.03M 0.65M
Net borrowings 0.16M 0.03M - 0.39M 2.46M
Total cash from financing activities 0.16M 0.03M 0.10M 0.39M 2.46M
Net income -0.31M -0.70M -3.71M -3.72M -3.19M
Change in cash -0.01M -0.10M 0.01M -1.26M 0.61M
Begin period cash flow 0.03M 0.13M 0.12M 1.39M 0.78M
End period cash flow 0.02M 0.03M 0.13M 0.12M 1.39M
Total cash from operating activities -0.17M -0.24M -0.11M -1.68M -2.49M
Depreciation 0.00M 0.07M 0.16M 0.20M 0.22M
Other cashflows from investing activities - 0.11M - - -
Change to account receivables 0.00M 0.09M -0.01M 0.12M -0.01M
Other cashflows from financing activities 0.16M 0.03M - - -
Change to netincome - - - 1.44M 0.54M
Capital expenditures 0.00M 0.00M 0.00M 0.00M 0.00M
Change in working capital 0.10M 0.13M 0.47M 0.41M -0.06M
Stock based compensation 0.00M 0.14M 0.18M - -
Other non cash items 0.04M 0.11M 2.78M 1.44M 0.54M
Free cash flow -0.17M -0.25M -0.11M -1.68M -2.49M

Peer Comparison*

Sector: Healthcare Industry: Biotechnology

Stock Name
Change
(USD)
Price
(USD)
Trailing
PE (x)
Forward
PE (x)
Price Sales
TTM (x)
Price to Book Value (x)
Enterprise Value
to Revenue (x)
Enterprise Value
to EBITDA (x)
CNBX
Cannabics Pharmaceuticals Inc
-
-%
0.00 - - 0.90 20.39 6.29 -0.49
NVO
Novo Nordisk A/S
0.98
2.41%
41.63 41.58 31.15 2.13 32.99 2.11 4.70
VRTX
Vertex Pharmaceuticals Inc
-4.02
0.74%
538.60 30.22 24.27 10.36 6.50 9.99 24.66
REGN
Regeneron Pharmaceuticals Inc
4.28
0.45%
955.47 29.07 20.12 7.57 3.82 6.95 19.42
ARGNF
argenx SE
64.70
7.19%
965.00 45.77 31.25 13.84 7.12 11.38 36.06

Profile*

Cannabics Pharmaceuticals Inc

CNBX Pharmaceuticals Inc., a clinical-stage company, engages in the discovery, development, and commercialization of novel cannabinoid-based products and technologies for the treatment of cancer. Its lead product candidate is Cannabics SR, an oral capsule developed for the treatment of patients with advanced cancer and cancer anorexia cachexia syndrome. The company is also developing various drug candidates, including PLP-33 for the local treatment of lateral spreading, or sessile, colorectal polyps during colonoscopy, BRST-33 for the treatment of breast cancer, MLN-33 for the treatment of melanoma, and PRST-33 for the treatment of prostate cancer. In addition, it is developing RCC-33, an oral capsule containing a formulation of cannabinoids for the treatment of colorectal cancer. The company was formerly known as Cannabics Pharmaceuticals Inc. and changed its name to CNBX Pharmaceuticals Inc. in March 2022. CNBX Pharmaceuticals Inc. was incorporated in 2004 and is based in Bethesda, Maryland.

#3 Bethesda Metro Center, Bethesda, MD, United States, 20814

877 424 2429

1

Name Title Year Born
Mr. Gabriel Yariv Pres, COO & Exec. Chairman 1976
Mr. Eyal Barad Co-Founder, CEO & Director 1965
Mr. Uri Ben-Or CPA, CPA, M.B.A., MBA Chief Financial Officer 1970
Dr. Sanja Goldberg Chief Technology Officer 1976
Noam Permont VP of PR & Investor Relations NA
Dr. Sigalit Ariely-Portnoy Ph.D. Sr. Advisor of Regulation, Validation & Quality and Member of Advisory Board 1964
Dr. Tal Mofkadi Ph.D. Financial Advisor & Member of Advisory Board NA
Mr. Yasha Borstein Chief Data Officer 1963
Dr. Yaakov Waksman Head of Cannabidiol Research 1952
Dr. Ilya Reznik M.D. Head of Neuropsychiatry Devel. NA

Disclaimer - (*)This information, including any data, is sourced from Unicorn Data Services SAS, trading as EOD Historical Data (“EODHD”) on an ‘as is’ basis, using their API. We cannot guarantee the completeness or validity of the information and data provided on this page, as well as via the API. In some cases, the data may include analyst ratings or recommendations sourced through the EODHD API, which are intended solely for general information purposes.
This information does not consider your personal objectives, financial situation, or needs. Kalkine is not liable for any errors or omissions in the information provided or for any actions taken in reliance on it. You should seek advice from a financial adviser, stockbroker or other professional adviser (including taxation and legal advice) as necessary before acting on this information.

Support

Hi! How can we help you today?

Loading…